Merck & Co., Inc.
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Merck & Co., Inc. reported 12 stock positions worth $276.3 million. Its top holding was Personalis (PSNL) at 40.5% of the portfolio, followed by Moderna (MRNA, 24.6%) and Kymera Therapeutics (KYMR, 21.7%). Compared with Q3 2025, it sold out of 1. The biggest sale was an exit from Lava Therapeutics (LVTX).
- Most Recent 13F
- Q2 2026
- Location
- RAHWAY, NJ
- CIK
- 0000310158
- Portfolio Value
- $276.3M (Q4 2025)
- SEC Filing
- 0000310158-26-000055 ↗ filed Feb 17, 2026
Holdings Value
Holdings 12 stocks · $276.3M
| PSNL Personalis Inc. | 40.47% | 14,044,943 | $111.8M | No change |
| MRNA Moderna Inc. | 24.64% | 2,308,190 | $68.1M | No change |
| KYMR Kymera Therapeutics Inc. | 21.75% | 772,165 | $60.1M | No change |
| ENTRADA THERAPEUTICS INC | 6.47% | 1,739,768 | $17.9M | No change |
| EVAX Evaxion Biotech A/S | 2.10% | 1,214,126 | $5.8M | No change |
| ALEC Alector Inc. | 2.00% | 3,545,719 | $5.5M | No change |
| STRO Sutro Biopharma Inc. Com SHS | 1.14% | 272,351 | $3.2M | No change |
| VRDN Viridian Therapeutics Inc. | 1.05% | 93,414 | $2.9M | No change |
| XLO Xilio Therapeutics Inc. | 0.34% | 1,483,758 | $950K | No change |
| CARM Carisma Therapeutics Inc. | 0.02% | 1,473,240 | $63K | No change |
| NEUP Neuphoria Therapeutics Inc. | 0.01% | 10,027 | $39K | No change |
| HURA Tuhura Biosciences Inc. | 0.00% | 13,950 | $11K | No change |
Portfolio Sells Q3 2025 → Q4 2025
| LVTX Lava Therapeutics NV | Sold out | 0.00% | −0.79 |
Portfolio Buys Q3 2025 → Q4 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $526.4M | PSNL, MRNA, KYMR, AKTS, EIKN |
| Q1 2026 | 14 | $349.4M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, EIKN |
| Q4 2025 | 12 | $276.3M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, EVAX |
| Q3 2025 | 13 | $228.0M | PSNL, MRNA, KYMR, ALEC, ENTRADA THERAPEUTICS INC |
| Q2 2025 | 13 | $215.6M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q1 2025 | 12 | $164.3M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q4 2024 | 13 | $258.0M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |